- Injective’s on-chain metrics showed that the recent breakout past $14.4 offered a good buying opportunity.
- Demand for the token has slowed down in the past two weeks, but this was only a minor cause for concern.
Injective [INJ] was up 8.2% in 24 hours, and the daily trading volume was up nearly 40%, which was a bullish sign.
The surge in volume came when the price challenged the $14 resistance zone, and the move beyond this level was carried by high demand.
Source: INJ/USDT on TradingView
The one-day price chart illustrates INJ’s bullish bias in recent weeks. It formed a range below $11 in March and April.
That rally wasn’t random—it came with rising volume and was backed by clear structure.
The A/D indicator attested to the increased demand with its higher highs and higher lows since April. This uptrend has slowed down over the past two weeks.
The balance between bulls and bears was more neutral now.
Yet, Injective managed to breach the local $14.42 resistance, a level marked by the 78.6% Fibonacci retracement at $14.16.
The MACD flashed a bullish crossover, suggesting momentum was swinging back in favor of buyers.
Therefore, the move beyond $14.2-$14.4 was a firm sign of bullish intent. Increased buying volume would sustain the rally and potentially push it as high as $18.6 or $22.4.
Injective traders might not want to wait for lofty targets.
On Bybit’s Liquidation Heatmap, a dense cluster appeared around $15-$15.5 and could pull INJ higher. Thereafter, the token might need time for consolidation before its next impulse move higher.
This is the move that metrics signaled investors could buy.
INJ metrics flash buy signal – Is it too late?
The data from Santiment showed that Development Activity has been fairly steady in 2025, despite the volatile price trends. This was a good sign for long-term investors.
Another positive sign was the uptrend in the Mean Coin Age since late January.
It reflected network-wide accumulation, as the token traded within a range for two months. The recent breakout saw some profit-taking in late April, but the metric was rising once more.
Additionally, the 180-day MVRV remained in negative territory.
That meant — holders in this period were still at a loss on average, and that in turn meant the price was not at a high risk from profit-taking activity.
Together, the network metrics and the price chart indicated that Injective presented a buying opportunity. The steady daily active addresses and development activity on-chain were also encouraging factors.
